Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3

Conditions

Neuroendocrine Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Zollinger-Ellison Syndrome 1Thyroid Cancer, Papillary 1Somatostatinoma 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × pazopanib × Endocrine × Clear all
NCT01841736 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
44 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT01099540 2015-12-29

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Samsung Medical Center

Phase 2 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡